Role of nutriceutical agents in cardiovascular diseases: An update - Part I

Cardiovascular Reviews and Reports

Volumn 24, Issue 7, 2003, Pages 381-385+391

  Safi, Arshad M ^a   Samala, Cynthia A ^b   Stein, Richard A ^a  

^a BROOKLYN HOSPITAL CENTER   (United States)

^b Veterans Affairs NY Harbor Healthcare System Room 13051 C   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ARGININE; CARNITINE; CREATINE; FLAVONOID; GLUTATHIONE; RESVERATROL; SELENIUM; SITOSTEROL; TAURINE; UBIDECARENONE;

ALTERNATIVE MEDICINE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NUTRIENT; RESTENOSIS; REVIEW; STABLE ANGINA PECTORIS;

EID: 0038692954     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Adams KE, Cohen MH, Eisenberg D, et al. Ethical consideration of complementary and alternative medical therapies in conventional settings. Ann Intern Med. 2002;137:660-664.
2. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373-376.
3. Lerman A, Burnett JC, Higano ST, et al. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998;97:2123-2128.
4. Blum A, Porat R, Rosenschein U, et al. Clinical and inflammatory effects of dietary L-arginine in patients with intractable angina pectoris. Am J Cardiol. 1999;83(10):1488-1490.
5. Adams MR, McCredie R, Jessup W, et al. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis. 1997;129:261-269.
6. Blum A, Hathaway L, Mincemoyer R, et al. Oral L-arginine in patients with coronary artery disease on medical management. Circulation. 2000;101:2160-2164.
7. Quyyumi AA. Does acute improvement of endothelial dysfunction in coronary artery disease improve myocardial ischemia? A double-blind comparison of parenteral D- and L-arginine. J Am Coll Cardiol. 1998;32:904-911.
8. Boger RH, Bode-Boger SM, Thiele W, et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation. 1997;95:2068-2074.
9. Boger RH, Bode-Boger SM, Thiele W, et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol. 1998;32:1336-1344.
10. Katz AD, Khan T, Zeballos GA, et al. Decreased activity of the Larginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation. 1999;99:2113-2117.
11. Bocchi EA, Moraes AV, Esteves-Filho A, et al. L-arginine reduces heart rate and improves hemodynamics in severe congestive heart failure. Clin Cardiol. 2000;23:205-210.
12. Rector TS, Bank AJ, Mullen KA, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation. 1996;93:2135-2141.
13. Hambrecht R, Hilbrich L, Erbs S, et al. Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. J Am Coll Cardiol. 2000;35:706-713.
14. Suzuki T, Hayase M, Hibi K, et al. Effect of local delivery of Larginine on in-stent restenosis in humans. Am J Cardiol. 2002;89:363-367.
15. Creager MA, Gallagher SJ, Girerd XJ, et al. L-arginine improves endothelial dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90:1248-1253.
16. Boger RH, Bode-Boger SM, Brandes RP, et al. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits. Circulation. 1997;96:1282-1290.
17. Toutouzas PC, Tousoulis D, Davies GJ. Nitric oxide synthesis in atherosclerosis. Eur Heart J. 1998;19:1504-1511.
18. Mohri M, Ichiki T, Hirooka Y, et al. Endogenous nitric oxide prevents myocardial ischemia in patients with hypertension and left ventricular hypertrophy. Am Heart J. 2002;143:684-689.
19. Houghton JL, Philbin EF, Strogatz DS, et al. The presence of African American race predicts improvement in coronary endothelial function after supplementary L-arginine. J Am Coll Cardiol. 2002;39:1314-1322.
20. Azuma J, Sawamura A, Awata N, et al. Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. Clin Cardiol. 1985;8:276-282.
21. Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic heart failure and its prospective application. Jpn Circ J. 1992;56:95-99.
22. Jeejeebhoy F, Keith M, Freeman M, et al. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J. 2002;143:1092-1100.
23. Nonaka H, Tsujino T, Watari Y, et al. Taurine prevents the decrease in expression and secretion of extracellular superoxide dismutase induced by homocysteine. Amelioration of homocysteine-induced endoplasmic reticulum stress by taurine. Circulation. 2001;104:1165-1170.
24. Yamori Y, Nara Y, Ikeda K, et al. Is taurine a preventive nutritional factor of cardiovascular diseases or just a biological marker of nutrition? Adv Exp Med Biol. 1996;403:623-629.
25. 10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 1990;65:521-523.
26. 10 treatment. Clin Investig. 1993;71(8 suppl):S140-S144.
27. 10 as an adjunctive in treatment of congestive heart failure. Am J Cardiol. 1992;(suppl 19):216A.
28. 10 of patients in heart failure who are eligible or ineligible for a transplant. Biochem Biophys Res Commun. 1992;182:247-253.
29. 10. Mol Aspects Med. 1994;15: S287-S294.
30. 10 in patients with congestive heart failure. Ann Intern Med. 2000;132:636-640.
31. 10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol. 1985;56:247-251.
32. 10 during heart surgery. Clin Investig. 1993;71:S155-S161.